Pds biotech initiates versatile-002 phase 2 combination trial of pds0101-keytruda® in recurrent/metastatic head and neck cancer in collaboration with merck

Versatile-002 trial for first line treatment of recurrent/metastatic head and neck cancer with combination pds0101-keytruda® is now open and recruiting patients versatile-002 trial for first line treatment of recurrent/metastatic head and neck cancer with combination pds0101-keytruda® is now open and recruiting patients
PDSB Ratings Summary
PDSB Quant Ranking